Diary - News All news BIOASTER in collaboration with Janssen and the CRCL

BIOASTER in collaboration with Janssen and the CRCL

BIOASTER announces Hepatitis B Collaboration with Janssen and the Cancer Center of Lyon (CRCL).

Objective of the collaboration: bring a predictive model for the development of novel therapies.

BIOASTER, and Cancer Center of Lyon (CRCL, France) represented by its managing partners INSERM1, CNRS2, UCBL3 and CLB4, have signed a contract with Janssen-Cilag SAS, one of the Janssen Pharmaceutical Companies of Johnson & Johnson to advance the global fight against chronic hepatitis B virus (HBV). The collaboration is jointly coordinated by Janssen France and Johnson & Johnson Innovation.

Read the press release

To go further...

See BIOASTER profil

Headlines

Our members

Adocia renforce sa trésorerie de 19 millions d’euros à la suite d’une opération immobilière

March 29^th, 2022

Lys Therapeutics and Inserm Transfert sign a three-year agreement

March 4^th, 2022

Nosopharm signs partnership with INRAE and University of Montpellier to develop new anti-infectives

March 15^th, 2022

All news